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Opioid overdose is a major cause of premature mortality and life-years lost not only in Eastern 
Europe but in Scotland, as confirmed by the Global Burden of Disease Study 20151.  
Scotland’s opioid-related deaths averaged 400 per annum in 2006-102: and 10% of them occurred in 
the 4-weeks after prison-release. Annually, around 30,000 clients receive methadone-substitution 
therapy3, which is continued in Scottish prison custody4.  
In 2005, the opioid antagonist naloxone was added to UK’s exempt list of prescription-only 
medicines that could be administered intramuscularly by anyone in an emergency to safe life. In 
January 2011, Scotland became the first country to introduce a centrally-funded, evaluated National 
Naloxone Programme (NNP), designed to have 80% power within 3-years to detect a 30% reduction 
(from 10% to 7%) in its primary outcome: the proportion of opioid-related deaths within 4-weeks aof 
prison-release2. By 2014+15 (calendar years), the primary outcome had reduced to 4%5, a 60% 
reduction compared to 2006-10, see Table 1. 
Every two years, Scotland’s Needle Exchange Surveillance Initiative (NESI), which is geographically 
representative of Scotland’s problem drug users, interviews over 2000 people who have recently 
injected drugs (80% of them within the past 6 months). Ethical approval for NESI was obtained from 
the NHS West of Scotland Research Ethics Committee. From 2011, NESI asked interviewees about 
the prescription of take-home naloxone in the past-year, and whether their most recent prescription 
was from prison6. The percentage of NESI respondents prescribed take-home naloxone in the past 
year increased from 8% in 2011/12 (financial year) through 32% in 2013/14 to 51% in 2015/16, 
mirroring the increased effectiveness of Scotland’s NNP in 2014+2015 (p = 0.013), see Table 1.  
There was, however, a significant decrease in the proportion of take-home nalxoone supplied to 
NESI respondents by Scottish prisons between 2013/14 and 2015/16 (p = 0.0018), perhaps because 
regional targets were set (and met) for community-based provision of take-home naloxone to 15% 
of the regions’ problem drug users by the end of 2013/14 (rising to 30% by the end of 2015/16)  and 
before prison-based advisory targets were introduced in 2014/152. We found important 
heterogeneity of provision of take-home naloxone by gender, age-group, homelessness and recency 
of injecting with greater provision for people younger than 35 years, the homeless and those who 
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had injected drugs in the past 6 months, see Table 2; however, the proportion whose naloxone was 
most recently received from prison was 13% irrespective of recency of injecting.  
When past-year incarceration-rate and average duration of incarceration are taken into account6, 
Table 2 shows that Scottish prisons provided take-home naloxone to 67% (95% CI: 53 to 81) of NESI’s 
female past-year prisoner-releases but to only 39% of their male counterparts (34 to 44); and to 48% 
(40 to 55) of past-year NESI prisoner-releases aged less than 35 years but to only 37% (31 to 43) of 
their older counterparts. Community-provision in the past-year was higher for females than males, 
for those aged less than 35 years than for those aged 35 years or older, and higher for NESI 
interviewees who had been homeless in the past 6-months than for those who had not. However, 
community provision was noticeably low at 28% (24 to 32) for those with a history of injection drug 
use who had not injected in the past 6-months.  
As a safeguard against increasing numbers of age-related opioid deaths, naloxone provision should 
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within 4 weeks of 
prison release* 




had been in 
prison in the past 
year (%, n/N) 
Mean length of 
incarceration 
(weeks) 
Percentage of responders 
who had been 
prescribed take-home 
naloxone in the past year  
(%,  n/N) 
Percentage of 
those prescribed 
naloxone in the 
past year who 
received it most 
recently from 
prison (%, n/N) 
2006–10  
(5 years) 
1970 193  
(9·8%; 8·5–11·1) 
2011/12   17% (367/2154)  5·0    8% (  175/2146)  16%  ( 27/  168) 
2011–13  
(3 years) 
1212   76  
(6·3%; 4·9–  7·6) 
2013/14   20% (458/2342) 5·4  32% (  745/2331)  19%  (138/ 732) 
2014–15  
(2 years) 
  942   37  
(3·9%; 2·7–  5·2) 
2015/16   17% (448/2696) 5·0  51% (1383/2696)  13%  (186/1383) 
 
Table 1: Primary effectiveness of Scotland’s NNP in reducing opioid-related deaths with a 4-week antecedent of prison release and increasing past-year 
prescriptions of take-home naloxone to people who inject drugs 
 
Periods given span 5 calendar-years before and after start of Scotland’s continuing National Naloxone Programme (NNP). Information on past-year 






Table 2: Heterogeneity in past-year prescribing of take-home naloxone, to whom and whether in the 
community or prison-based: by gender, age-group, homelessness in the past 6-months, injecting in 

























































95% confidence interval for 
difference 
   
-8.0% to   0.3% 
 
6.1% to 12.9% 
Male 39% 46% 21% 
(405/1910) 
4.9  50%  
(  954/1898) 
 16%   
(157/  954) 
Female 67% 52% 6%  
(  43/   769) 
5.6  54%  
(  417/  768) 
   7%   





95% confidence interval for 
difference 
 
9.6% to 18.0% 
 
3.5% to 11.8% 
< 35    years 48% 55% 23%  
(178/  770) 
5.1  61%  
(  466/  768) 
 18%   
(  84/  466) 
   35+ years 37% 43% 13% 
(234/1748) 
5.0  47%  
(  813/1737) 
 10%   
(  85/  813) 
 
HOMELESSNESS in past 6-months 
 
95% confidence interval for 
difference 
 
6.0% to 15.6% 
 
9.2% to 19.5% 
Yes 46% 55% 34%  
(197/  584) 
5.7  62%  
(  355/  577) 
 25%   
(  90/  355) 
No 41% 46% 14% 
(187/1363) 
4.2  51%  
(  689/1359) 
 11%   
(  76/  689) 
 
INJECTING  in past 6-months 
 
95% confidence interval for 
difference 
 
20.7% to 29.9% 
 
-7.4% to 4.6% 
Yes, in  
past 6-months 
43% 52% 18% 
(388/2207) 
4.9  56% 
(1233/2196) 
 13%  
(164/1233) 
Ever, but not 
past 6-months 
37% 28% 12%  
(  60/   487) 
5.5  31%  
(  149/  486) 
 15%   
(  22/  149) 
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